The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
In a historic medical breakthrough, Northwestern Medicine surgeons successfully split a deceased donor’s liver to save two ...
Investor's Business Daily on MSN5h
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
CHRONIC liver disease cases will rocket by more than 54 per cent in coming decades, it has been predicted. Public health ...
Barclay Missen had resigned himself to hospice care.Missen, a 53-year-old from Chicago, got diagnosed with stage IV ...
The biotech unveiled a new research program in alpha-1 antitrypsin deficiency, a disease that’s also a focus for rival Beam ...
When an organ is injured, our body initiates a healing process. If the injury is repeated or chronic, it can lead to an ...
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Understanding liver fibrosis progression through machine learning provides valuable insights into disease mechanisms, ...
Sarepta Therapeutics Inc.'s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute liver ...
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback